In the case series reported here, we specifically focus on patients with MBM, who exclusively received triple-targeted therapy of REGO + BRAF/MEKi in BRAFmut melanoma and REGO + MEKi in NRASmut melanoma. This evidence concerns the gene BRAF and melanoma.